Ruxolitinib, a known inhibitor of the JAK/STAT3 pathway approved for myelofibrosis, has been shown in a Phase 1 trial to lead to responses in approximately a third of patients with relapsed/refractory MM (94). Here, STAT3 is linked to Miyoshi myopathy.